Literature DB >> 24570902

Molecular targeted therapy for biliary tract malignancy: defining the target.

Sarah B Fisher1, Kevin E Fisher2, Shishir K Maithel1.   

Abstract

Entities:  

Year:  2012        PMID： 24570902      PMCID： PMC3924630          DOI： 10.3978/j.issn.2304-3881.2012.10.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  11 in total

Review 1.  Biliary tract cancers.

Authors:  P C de Groen; G J Gores; N F LaRusso; L L Gunderson; D M Nagorney
Journal:  N Engl J Med       Date:  1999-10-28       Impact factor: 91.245

2.  Biliary-tract cancer: improving therapy by adding molecularly targeted agents.

Authors:  Lars Henrik Jensen
Journal:  Lancet Oncol       Date:  2011-12-20       Impact factor: 41.316

Review 3.  Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.

Authors:  Lars Henrik Jensen; Anders Jakobsen
Journal:  Expert Rev Anticancer Ther       Date:  2011-04       Impact factor: 4.512

Review 4.  Biliary tract carcinomas: from chemotherapy to targeted therapy.

Authors:  Donatella Marino; Francesco Leone; Giuliana Cavalloni; Celeste Cagnazzo; Massimo Aglietta
Journal:  Crit Rev Oncol Hematol       Date:  2012-07-17       Impact factor: 6.312

5.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

6.  Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Authors:  Jeeyun Lee; Se Hoon Park; Heung-Moon Chang; Jun Suk Kim; Hye Jin Choi; Myung Ah Lee; Joung Soon Jang; Joung Soon Chang; Hei Cheul Jeung; Jung Hun Kang; Hyun Woo Lee; Dong Bok Shin; Hye Jin Kang; Jong-Mu Sun; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim
Journal:  Lancet Oncol       Date:  2011-12-20       Impact factor: 41.316

7.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

8.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

9.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
View more
  4 in total

1.  A novel PTEN gene promoter mutation and untypical Cowden syndrome.

Authors:  Chen Liu; Guangbing Li; Rongrong Chen; Xiaobo Yang; Xue Zhao; Haitao Zhao
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

2.  Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Authors:  Kevin E Fisher; Jigna C Jani; Sarah B Fisher; Cora Foulks; Charles E Hill; Collin J Weber; Cynthia Cohen; Jyotirmay Sharma
Journal:  J Surg Res       Date:  2013-05-23       Impact factor: 2.192

3.  Retrospective evaluation of endoscopic stenting of combined malignant common bile duct and gastric outlet-duodenum obstructions.

Authors:  Jianfeng Yu; Jianyu Hao; Dongfang Wu; Haibo Lang
Journal:  Exp Ther Med       Date:  2014-08-11       Impact factor: 2.447

4.  Differential Diagnosis of Immunoglobulin G4-associated Cholangitis From Cholangiocarcinoma.

Authors:  Shunda Du; Gang Liu; Xinqi Cheng; Yue Li; Qian Wang; Ji Li; Xin Lu; Yongchang Zheng; Haifeng Xu; Tianyi Chi; Haitao Zhao; Yiyao Xu; Xinting Sang; Shouxian Zhong; Yilei Mao
Journal:  J Clin Gastroenterol       Date:  2016-07       Impact factor: 3.062
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.